Division of Endocrinology, Metabolism and Molecular Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Clinical Research, CGParkin Communications, Inc., Henderson, Nevada, USA.
Diabetes Technol Ther. 2021 Oct;23(10):715-725. doi: 10.1089/dia.2021.0196. Epub 2021 Jun 17.
Numerous studies have demonstrated the clinical value and safety of insulin pump therapy in type 1 diabetes and type 2 diabetes populations. However, the eligibility criteria for insulin pump coverage required by the Centers for Medicare & Medicaid Services (CMS) discount conclusive evidence that supports insulin pump use in diabetes populations that are currently deemed ineligible. This article discusses the limitations and inconsistencies of the insulin pump eligibility criteria relative to current scientific evidence and proposes workable solutions to address this issue and improve the safety and care of all individuals with diabetes.
大量研究表明胰岛素泵治疗在 1 型和 2 型糖尿病患者中的临床价值和安全性。然而,医疗保险和医疗补助服务中心(CMS)规定的胰岛素泵报销资格所需的明确证据支持目前被认为不合格的糖尿病患者使用胰岛素泵。本文讨论了胰岛素泵资格标准相对于当前科学证据的局限性和不一致性,并提出了切实可行的解决方案,以解决这一问题,提高所有糖尿病患者的安全性和护理水平。